Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
Status:
Completed
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The aim is to demonstrate equivalent efficacy and safety in the treatment of the two most
frequent forms of cervical dystonia (predominantly rotational torticollis and predominantly
laterocollis) with the standard initial dose of 500 units Dysport®. The patients will be
assigned to one of the two basic types of cervical dystonia, either predominantly rotational
torticollis or predominantly laterocollis on the basis of clinical examination. This will
determine which therapy is to be administered, using the clearly defined, structured
injection protocols.
Phase:
Phase 3
Details
Lead Sponsor:
Ipsen
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA